You run the same playbook here, nitpicking timelines, downplaying regulatory positioning, and moving the goalposts whenever NWBO advances. Your post history speaks for itself.
You’re responding to my GME analogy, so let’s be clear: it’s not about business models. It’s about market mechanics, how a suppressed float meets a binary catalyst. Different asset class, same structural setup. The biology, the trial results, the MHRA regulatory pathway, and the GMP infrastructure are all real, public, and advancing whether you approve of the comparison or not.
Your Autolus example is irrelevant. Autolus is scaling autologous CAR-T with massive inpatient cost and a hospital-dependent distribution model. NWBO is deploying a process-defined, tissue-agnostic dendritic cell platform that can be manufactured anywhere with Eden automation, already validated at Advent under MHRA licensure. That is why UK MHRA approval matters, because the UK is a WHO-Listed Authority. Approval there isn’t a “trivial market,” it’s a trigger for reliance markets like Canada, Australia, and Singapore, with legal reciprocity already built into their frameworks.
And since you stay relentlessly negative on one very specific small-cap biotech, let’s be transparent, which hedge fund pays you to monitor this ticker full-time? Or do you just spend your free time doing forensic pessimism on a single company’s stock for fun? Either way, your agenda is showing.
Bullish
Market Data 
Markets 
AI
